Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
View Digital Edition
Original Article
Tolerability of Carboplatin When Using Rounded Serum Creatinine Values
Daniel J. Bestul, PharmD, BCOP
,
Amy L. Mazloom, PharmD
Drug Profiles/Updates
A Review of PARP Inhibitors in Clinical Development
Sarah Hopps, PharmD
,
Carla D. Kurkjian, MD
,
Shubham Pant, MD
From the Literature
,
From the Literature
Bevacizumab Delays Progression in Women with Advanced Ovarian Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
From the Literature
,
From the Literature
Combination Therapy with Pertuzumab Offers New Option in Metastatic Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
From the Literature
,
From the Literature
Chemotherapy-Induced Changes in Brain Structure Correlate with Cognitive Dysfunction
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
From the Literature
,
From the Literature
BRAF Inhibitor Therapy Linked to Squamous-Cell Carcinoma in Patients with RAS Mutations
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
From the Literature
,
From the Literature
Adding Bevacizumab to Neoadjuvant Chemotherapy Improves Complete Response Rates in Patients with Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Results 1 - 7 of 7